By vgreene, 25 March, 2021 Risk of recurrence among isolated heterozygous carriers for either the factor V Leiden or prothrombin G20201A mutations is relatively low and insufficient to warrant secondary prophylaxis after 1st clot in absence of other independent predictors of recurr
By vgreene, 25 March, 2021 Consider extended tx after 1st clot in pts w antithrombin protein C or protein S deficiency uarr basal Factor VIII activity substantial hyperhomocysteinemia combined heterozygosity for 1 hereditary thrombophilia e g heterozygous for the factor V Leiden an
